Drugs / CAR-T cells targeting EpCAM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03563326 | Aug 2018 → Dec 2019 | gastric neoplasm, metastatic neoplasm, secondary malignant neoplasm | Jian-Kun Hu | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T cells targeting EpCAM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03563326 ↗ |
| Action | Deplete | “Chimeric antigen receptor modified T (CAR-T) cells have the capability in targeting and recognizing tumor antigen, and can specifically recognize, bind and kill tumor cells...” NCT03563326 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor modified T (CAR-T) cells have the capability in targeting and recognizing tumor antigen, and can specifically recognize, bind and kill tumor cells...” NCT03563326 ↗ |
| Route | Other | “intraperitoneal infusion” NCT03563326 ↗ |